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p<0.001) compared to those with control BRS group (total length <
60mm). The main target vessel in the FPJ group was the LAD (80.0%).
The incidence of periprocedural myocardial infarction (as deﬁned by a
creatinine kinase (CK) >2 times the upper limit of normal in addition
to a CK-MB elevation) was higher in the FPJ group (FPJ 16.1% vs.
control BRS group 8.8%: p¼0.20). The incidence of major adverse
cardiac events (deﬁned as a combination of all-cause death, follow-up
myocardial infarction and target vessel revascularization) tended to
be higher in the FPJ group (FPJ 15.8% vs. control BRS group 9.4%:
p¼0.35) at 1-year follow-up. Deﬁnite scaffold thrombosis was
observed in 1 patient who was treated with a FPJ and stopped clopi-
dogrel at 2 months after PCI. The incidence of target lesion revascu-
larization (per lesion) was signiﬁcantly higher in the FPJ group (FPJ
12.5% vs. control BRS group 5.0%: p¼0.01).
CONCLUSIONS The incidence of periprocedural MI and TLR was
higher in the FPJ group. FPJ treatment for diffuse long lesions appears
to be feasible taking into account the greater co-morbidity and lesion
complexity in this group.
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BACKGROUND The study has ascertained the long term beneﬁts of
coronary stenosis treatment with a bioresorbable scaffold eluting
everolimus.
METHODS In the ABSORB Cohort B multi-center, single arm trial, 45
patients (B1) and 56 patients (B2) underwent at different time points
serial quantitative coronary angiography (QCA), intra vascular ultra-
sound (IVUS) and optical coherence tomography (OCT). At 5 years 53
patients without Target Lesion Revascularization (TLR) were re-con-
sented to undergo a ﬁnal serial invasive imaging.
RESULTS Between 6 months/1 year and 5 years angiographic luminal
late loss (LLL) remained unchanged; B1 0.1419mm vs 0.130.33mm,
p¼0.7953, B2 0.230.28mm vs 0.180.32mm, p¼0.5685. When pa-
tients with a TLR were included LLL was 0.150.20 mm vs
0.150.24 mm, p¼0.8275 for B1 and 0.300.37 mm vs 0.320.48 mm,
p¼0.8204 for B2. For the entire cohort in-scaffold and in-segment
binary restenosis was 7.8% (5/64) and 12.5% (8/64), respectively. On
IVUS the minimum lumen area (MLA) of B1 decreased from
5.230.97 mm2 at 6 months to 4.891.81mm2 at 5 years (p¼0.04)
while it remained unchanged in B2 (4.950.91mm2 at 1 year,
4.841.28 mm2 at 5 years, p¼0.5). At 5 years the struts were no longer
discernable by OCT and IVUS. On OCT MLA in B1 decreased from
4.511.28mm2 at 6 months to 3.651.39mm2 at 5years (p¼0.01), while
it remained unchanged in B2 (4.351.09mm2 at 1 year, 4.121.38mm2
at 5 years, p¼0.24). In the entire Cohort B the 5-year Major Adverse
Cardiac Event (MACE) rate was 11.0% without any scaffold throm-
bosis, deﬁnite or probable.CONCLUSIONS At 5 years implantation of a bioresorbable scaffold
resulted in stable lumen dimensions, a low restenosis rate and a low
MACE rate.
CATEGORIES CORONARY: Stents: Bioresorbable Vascular Scaffolds
KEYWORDS Bioresorbable scaffold, Intravascular ultrasound, Optical
coherence tomography
TCT-12
Impact of overlap on long-term clinical outcomes in patients undergoing
everolimus-eluting bioresorbable vascular scaffolds implantation in
routine clinical practice: insights from the European multicenter GHOST-EU
registry
Luis Ortega-Paz,1 Giuseppe Giacchi,1 Salvatore Brugaletta,1
Manel Sabate,1 Davide Capodanno,2 Tommaso Gori,3 Holger Nef,4
Azeem Latib,5 Julinda Mehilli,6 Maciej Lesiak,7 Giuseppe Caramanno,8
Christoph Naber,9 Carlo Di Mario,10 Antonio Colombo,11
Piera Capranzano,12 Jens Wiebe,13 Aleksander Araszkiewicz,14
Salvatore Geraci,8 Stylianos A. Pyxaras,15 Alessio Mattesini,16
Toru Naganuma,17 Thomas Munzel,3 Corrado Tamburino2
1Department of Cardiology, Thorax Institute, Hospital Clínic, IDIBAPS,
Barcelona, Spain; 2University of Catania, Catania, Italy; 3University
Medical Center Mainz, Mainz, Germany; 4Justus-Liebig University of
Giessen, Giessen, Germany; 5Ospedale San Raffaele, Milan, Italy;
6Deutsches Herzzentrum Munich, Munich, Germany; 7Poznan
University of Medical Sciences, Poznan, Poland; 8San Giovanni di Dio
Hospital, Agrigento, Not applicable; 9Contilia Heart and Vascular
Centre, Elisabeth Krankenhaus Essen, Germany, Essen, Germany;
10Imperial College London, London, United Kingdom; 11EMO GVM
Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy;
12Ferrarotto Hospital, University of Catania, Catania, Italy; 13University
of Giessen, Medizinische Klinik I, Giessen, Germany; 14Department of
Cardiology, University of Medical Sciences, Poznan, Not applicable;
15Contilia Heart and Vascular Center, Essen, Germany; 16Careggi
Hospital, Florence, Italy; 17New Tokyo Hospital, Matsudo, Chiba
BACKGROUND Bioresorbable vascular scaffold (BVS) overlap is
frequent in long coronary lesions. Its impact into clinical outcomes is
unknown. We aims to compare the short and long-term clinical out-
comes between patients with overlap BVS implanted and those with
no-overlap BVS.
METHODS We analyzed the clinical outcomes of 1627 patients treated
with BVS in the Gauging coronary Healing with biOresorbable Scaf-
folding plaTforms in Europe (GHOST-EU) registry, according to im-
plantation of overlap scaffolds. Primary endpoint was patient oriented
composite endpoint (POCE) of: all-cause death, any myocardial
infarction (MI) and any percutaneous coronary intervention. Device
oriented composite endpoint (DOCE) of cardiac death, target-vessel
(TV) MI and TV-revascularization was also analyzed. Scaffold throm-
bosis, according to ARC deﬁnition, was also collected. Follow-up was
performed at 1 and 12 months.
RESULTS A total of 287 (17.6%) patients were treated with overlap
BVS. The remaining 1340 (82.4%) received BVS not overlap. The
overlap group had signiﬁcantly higher prevalence of diabetes melli-
tus, acute coronary syndrome, B2/C lesion type, SYNTAX score 22,
lesion length >34 mm, use of intracoronary imaging during implan-
tation, pre and post-dilatation, dual antiplatelet duration. At 1-year,
POCE was not different between the overlap vs. no-overlap groups
(13.6% vs. 14.6%, p ¼ 0.712), even after adjustment for the difference
between the two groups. The DOCE was also no different between the
two groups (5.6% vs. 5.8%, p¼0.540). Rate of scaffold thrombosis did
not differ either at 30 days (1.4% vs. 1.2%, p¼0.768) or at 1-year (2.1%
vs. 2.2%, p¼1.000)
CONCLUSIONS In “Real-world” clinical practice, BVS overlap does
not appear to have an impact on outcomes and in particular on scaf-
fold thrombosis, whose rate is not negligible.
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